Ten patients received therapy, with an initial response seen in 7 out of 9 evaluable patients to date. Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.
Dr. Michael K. Schultz, Chief Scientific Officer at Perspective Therapeutics, presented research at the WWIC on the potential of lead-based targeted alpha particle therapy using [212Pb]VMT-α-NET for the treatment of neuroendocrine tumors (NETs)…
“We are pleased with our team’s progress in pioneering the development of promising image-guided, lead-based, alpha particle therapies.” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics…
Our team at Perspective Therapeutics continues to work diligently to advance much needed targeted alpha therapy using 212Pb,” said Thijs Spoor…
In the realm of medical treatments, especially those related to cancer, patients often come across various terminologies that might seem complex…
Radiation therapy has been an integral part of cancer treatment for many years. One specific method that’s been gaining attention is the use of radiation brachytherapy seeds…
First patient with MC1R-positive metastatic melanoma treated with 212Pb-VMT01… Preliminary data readout from dose escalation study expected Q4 2023…
• Phase I/2a clinical trials initiated: VMT-𝛼-NET for neuroendocrine tumors, and VMT01 for melanoma…
“We are delighted to announce the expansion of our collaboration with GT MedTech to increase our manufacturing in support of their objective of bringing GammaTile Therapy to more patients…
As a patient seeking to understand the various cancer treatment options available, brachytherapy may be a term that you come across. Brachytherapy is a specialized type of internal radiation therapy…
©2023. All rights reserved. Terms & Privacy | Privacy Policy
